Rapid Micro Biosystems, Inc. Class A Common Stock (RPID) Stock Price
RPIDStock
$0.76−74.00%52W
Market Cap$38.34M
P/E—
PEG Ratio—
Div yield—
Beta1.49
RPID Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-75.00%
Price vs S&P 500 (4W)-31.03%
VGM Score50.26
RPID Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.24 | -$0.27 | -10.96%(-$0.03) | |
| Q1 2026 | -$0.25 | -$0.31 | -25.67%(-$0.06) | |
| Q4 2025 | -$0.23 | -$0.28 | -23.53%(-$0.05) | |
| Q3 2025 | -$0.24 | -$0.26 | -6.12%(-$0.02) | |
| Q2 2025 | -$0.25 | -$0.27 | -6.58%(-$0.02) |
RPID Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.20
4.20
4.20
4.20
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
RPIDRapid Micro Biosystems, Inc. Class A Common Stock | B | B | F | 1.1x | 15.9% | 5.5% | -141.4% | $0.76 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
About Rapid Micro Biosystems, Inc. Class A Common Stock
Rapid Micro Biosystems automates microbial quality control testing for pharmaceutical and biotech manufacturers. Its Growth Direct platform modernizes manual testing workflows used in the production of biologics, vaccines, cell and gene therapies, and sterile injectables. The company generates revenue through system sales, consumables, software licensing, and related services.